Finance

Lists
STAR:NSE
Strides Pharma Science Ltd
₹999.50
-0.80%
(-8.10) 1D
Nov 6, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for STAR...
Open
₹1,002.60
High
₹1,009.00
Low
₹991.80
Mkt. cap
92.14B
Avg. vol.
347.50K
Volume
186.98K
Dividend
0.50%
Quarterly dividend
₹1.25
Ex-dividend date
Jul 31, 2026
P/E ratio
14.94
52-wk high
₹1,260.90
52-wk low
₹768.65
EPS
₹66.90
Shares outstanding
89.55M
No. of employees
4K
Open
₹1,002.60
High
₹1,009.00
Low
₹991.80
Mkt. cap
92.14B
Avg. vol.
347.50K
Volume
186.98K
Dividend
0.50%
Quarterly dividend
₹1.25
Ex-dividend date
Jul 31, 2026
P/E ratio
14.94
52-wk high
₹1,260.90
52-wk low
₹768.65
EPS
₹66.90
Shares outstanding
89.55M
No. of employees
4K
News stories
From web sources and news partners
Profile
Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered at Bangalore. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. The company partners with generic companies to supply retail and hospital generics in injectable products and softgels. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India. Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two companies. Arun Kumar is the founder and chairman, and has been on the board as managing director since its inception. Wikipedia
About Strides Pharma Science Ltd
CEO-
Employees3.54K
Founded1990
HeadquartersBengaluru, Karnataka, India
SectorHealth Care
IndustryPharmaceutical industry
Last report
Oct 30, 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (INR)
14.30B / 14.15B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
11.95B
13.23B
12.65B
14.30B
Cost of goods sold
4.63B
7.19B
4.95B
6.29B
Cost of revenue
4.63B
7.19B
4.95B
6.29B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.30B
3.45B
2.43B
2.38B
Operating expense
5.46B
4.91B
5.97B
6.07B
Total operating expenses
10.09B
12.10B
10.92B
12.36B
Operating income
1.85B
1.13B
1.73B
1.94B
Other non operating income
1.07B
-1.66B
48.90M
40.83M
EBT including unusual items
2.45B
1.48B
2.00B
1.50B
EBT excluding unusual items
2.49B
502.07M
1.36B
1.52B
Income tax expense
373.53M
187.70M
341.23M
163.18M
Effective tax rate
15.22%
12.68%
17.09%
10.85%
Other operating expenses
2.66B
928.53M
2.97B
3.11B
Net income
2.02B
1.27B
1.57B
1.31B
Net profit margin
16.92%
9.59%
12.40%
9.15%
Earnings per share
-
-
-
-
Interest and investment income
-
404.82M
-
-
Interest expense
-433.79M
-130.82M
-405.61M
-465.41M
Net interest expenses
-433.79M
274.00M
-405.61M
-465.41M
Depreciation and amortization charges
506.23M
532.49M
563.99M
572.15M
EBITDA
2.25B
1.55B
2.15B
2.51B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps